

Renal denervation in the management of hypertension in adults. A clinical consensus statement of the ESC Council on Hypertension and the European Association of Percutaneous Cardiovascular Interventions (EAPCI)

Emanuele Barbato¹, MD, PhD; Michel Azizi^{2,3}, MD; Roland E. Schmieder⁴, MD; Lucas Lauder⁵, MD; Michael Böhm⁵, MD; Sofie Brouwers⁶, MD, PhD; Rosa Maria Bruno^{2,7}, MD, PhD; Dariusz Dudek⁸, MD, PhD; Thomas Kahan⁹, MD, PhD; David E. Kandzari¹⁰, MD; Thomas F. Lüscher¹¹, MD; Gianfranco Parati¹², MD; Atul Pathak¹³, MD, PhD; Flavio L. Ribichini¹⁴, MD; Markus P. Schlaich¹⁵, MD; Andrew S.P. Sharp¹⁶, MD; Isabella Sudano¹⁷, MD, PhD; Massimo Volpe¹⁸, MD; Costas Tsioufis¹⁹, MD; William Wijns^{20,21}, MD, PhD; Felix Mahfoud^{5*}, MD, MA

The authors' affiliations can be found in the Appendix paragraph.

This paper also includes supplementary data published online at: <https://eurointervention.pcronline.com/doi/10.4244/EIJ-D-22-00723>

This article has been co-published with permission in EuroIntervention and the European Heart Journal. All rights reserved.

The articles are identical except for minor stylistic and spelling differences in keeping with each journal's style. Either citation can be used when citing this article.

KEYWORDS

- hypertension
- renal sympathetic denervation
- resistant hypertension
- uncontrolled hypertension

Abstract

Since the publication of the 2018 European Society of Cardiology/European Society of Hypertension (ESC/ESH) Guidelines for the Management of Arterial Hypertension, several high-quality studies, including randomised, sham-controlled trials on catheter-based renal denervation (RDN) were published, confirming both the blood pressure (BP)-lowering efficacy and safety of radiofrequency and ultrasound RDN in a broad range of patients with hypertension, including resistant hypertension. A clinical consensus document by the ESC Council on Hypertension and the European Association of Percutaneous Cardiovascular Interventions (EAPCI) on RDN in the management of hypertension was considered necessary to inform clinical practice. This expert group proposes that RDN is an adjunct treatment option in uncontrolled resistant hypertension, confirmed by ambulatory BP measurements, despite best efforts at lifestyle and pharmacological interventions. RDN may also be used in patients who are unable to tolerate antihypertensive medications in the long term. A shared decision-making process is a key feature and preferably includes a patient who is well informed on the benefits and limitations of the procedure. The decision-making process should take (i) the patient's global cardiovascular (CV) risk and/or (ii) the presence of hypertension-mediated organ damage or CV complications into account. Multidisciplinary hypertension teams involving hypertension experts and interventionalists evaluate the indication and facilitate the RDN procedure. Interventionalists require expertise in renal interventions and specific training in RDN procedures. Centres performing these procedures require the skills and resources to deal with potential complications. Future research is needed to address open questions and investigate the impact of BP-lowering with RDN on clinical outcomes and potential clinical indications beyond hypertension.

*Corresponding author: Klinik für Innere Medizin III - Kardiologie, Angiologie und Internistische Intensivmedizin, Universitätsklinikum des Saarlandes and Saarland University, Gebäude 41, Kirrberger Str. 100, 66421 Homburg, Germany. E-mail: felix.mahfoud@uks.eu

Abbreviations

BP	blood pressure
CCB	calcium channel blocker
CTA	computed tomography angiography
CV	cardiovascular
EAPCI	European Association of Percutaneous Cardiovascular Interventions
ESC	European Society of Cardiology
ESH	European Society of Hypertension
HARC	Hypertension Academic Research Consortium
KDIGO	Kidney Disease Improving Global Outcomes
MACE	major adverse cardiovascular events
MDHT	multidisciplinary hypertension team
MRA	magnetic resonance angiography
PROM	patient-related outcome measures
PVI	pulmonary vein isolation
RAS	renin-angiotensin system
RCT	randomised controlled trial
RDN	renal denervation
RF	radiofrequency
eGFR	estimated glomerular filtration rate

Introduction

High blood pressure (BP) is amongst the most prevalent modifiable cardiovascular (CV) risk factors and remains a leading cause of death¹. Despite a stable global prevalence, the absolute number of people with hypertension increased from 648 million in 1990 to 1.28 billion in 2019². Lowering BP through the use of antihypertensive drugs has been shown to reduce the risk for CV morbidity and all-cause mortality^{3,4}. However, disease awareness and BP control rates remain poor worldwide, especially in low- and middle-income countries and in low-income populations (especially in some ethnicities) residing in high-income countries^{2,5,6}.

Over the last two decades, device-based therapies have been investigated as additional treatment options for uncontrolled

hypertension. Of these, renal denervation (RDN) has the largest body of evidence for safety and efficacy⁷. Based on the data available at the time, the 2018 European Society of Cardiology (ESC) and the European Society of Hypertension (ESH) Guidelines for the Management of Arterial Hypertension provided the following recommendation: “Device-based therapies for hypertension are not recommended for the routine treatment of hypertension, unless in the context of clinical studies and randomised controlled trials, until further evidence regarding their safety and efficacy becomes available”⁸. Since the release of these Guidelines in 2018⁸, several trials have been published providing new evidence (**Figure 1**)⁹⁻¹³. Hence, a clinical consensus document was deemed necessary by the ESC Council on Hypertension and the European Association of Percutaneous Cardiovascular Interventions (EAPCI). The working group members were equally selected by the ESC Council on Hypertension and the EAPCI. The current paper reviews the evidence for the safety and efficacy of RDN, summarises aspects of the expert group’s discussion, and provides consensus statements for patient selection, centre requirements, procedural aspects, and considerations for future trial designs. In controversial areas, a consensus was achieved by voting and/or agreement of the expert panel after detailed discussions.

Review of clinical data

Table 1 provides the key characteristics of important published randomised clinical trials (RCTs), and **Table 2** summarises the characteristics of four ongoing sham-controlled trials investigating RDN for hypertension. These RCTs underwent a rigorous audit evaluating their scientific quality according to the following methodological characteristics: (i) sham-controlled, multicentre trials, (ii) adequate blinding of patients and outcome assessors, (iii) ambulatory BP change as the primary outcome, (iv) study completed as planned with outcome data available for all (or nearly all) randomised participants, and (v) use of second-generation RDN systems and procedural techniques^{14,15}.




Figure 1. Landmark RDN trials. Overview of important randomised controlled trials with (top) and without (bottom) an invasive sham-control group. Green indicates that the trial met its primary efficacy outcome; red indicates that the trial did not meet its primary efficacy outcome.

Table 1. Key characteristics of important randomised controlled RDN trials.

Trial, year of publication	Investigational device	Design (randomisation ratio)	Sample size	Inclusion criteria	Primary efficacy outcome	BP reduction in RDN vs control group
Randomised controlled trials						
Symplcity HTN-2, 2010 ⁹²	Symplcity Flex (mono-electrode RF)	Open-label, RDN vs control (1:1)	106	Uncontrolled office BP on ≥ 3 antihypertensive drugs	Change in office SBP at 6 months	-32 ± 23 vs -1 ± 21 mmHg; $p < 0.0001$
DENERHTN, 2015 ⁹³	Symplcity Flex (mono-electrode RF)	Open-label, SSAHT + RDN vs SSAHT (1:1)	106	Uncontrolled office and 24-hr BP on ≥ 3 antihypertensive drugs	Change in daytime ambulatory SBP at 6 months	-9.9 (95% CI: -13.6 to -6.2) vs -5.9 mmHg (95% CI: -11.3 to -0.5); $p = 0.033$
RADIOSOUND-HTN, 2019 ⁹⁴	Symplcity Spyrall (multi-electrode RF) vs Paradise (US)	US-RDN vs RF-RDN of the main artery vs RF-RDN of main artery vs RF-RDN of the branches, and accessory arteries (1:1:1)	120	Uncontrolled office and 24-hr BP on ≥ 3 antihypertensive drugs	Change in daytime ambulatory SBP at 3 months	US: -13.2 ± 13.7 mmHg vs RF main artery: 6.5 ± 10.3 mmHg vs RF including branches: -8.3 ± 11.7 mmHg ($p = 0.043$ for US vs RF main artery; $p > 0.99$ for RF main artery vs RF branches)
First-generation randomised sham-controlled trials						
Symplcity HTN-3, 2014 ¹⁶	Symplcity Flex (mono-electrode RF)	RDN vs sham (2:1)	535	Uncontrolled office and 24-hr BP on ≥ 3 antihypertensive drugs	Change in office SBP at 6 months	-14.1 ± 23.9 vs -11.7 ± 25.9 mmHg; $p = 0.27$
RSD-Leipzig, 2015 ⁹⁵	Symplcity Flex (mono-electrode RF)	RDN vs sham (1:1)	71	Uncontrolled 24-hr BP on ≥ 3 antihypertensive drugs	Change in 24-hr SBP at 6 months	-7.0 (95% CI: -10.8 to -3.2) vs -3.5 mmHg (95% CI: -6.7 to -0.2); $p = 0.15$
ReSET, 2016 ⁹⁶	Symplcity Flex (mono-electrode RF)	RDN vs sham (1:1)	69	Uncontrolled daytime ambulatory BP on ≥ 3 antihypertensive drugs	Change in daytime ambulatory SBP at 6 months	-6.1 ± 18.9 vs -4.3 ± 15.1 mmHg; $p = 0.66$
WAVE IV, 2017 ⁹⁷	Externally delivered therapeutic US energy (surround sound system)	RDN vs sham (1:1)	81	Uncontrolled office and 24-hr BP on ≥ 3 antihypertensive drugs	Change in office SBP	-13.2 ± 20 vs -18.9 ± 14 mmHg; $p = 0.181$
REDUCE-HTN: REINFORCE, 2020 ⁹⁸	Vessix (multi-electrode RF)	RDN vs sham (2:1)	51	Uncontrolled office and 24-hr BP in absence of antihypertensive drugs	Change in 24-hr SBP at 2 months	-5.3 (95% CI: -8.8 to -1.8) vs -8.5 mmHg (95% CI: -13.3 to -3.8); $p = 0.30$
Second-generation randomised sham-controlled trials						
SPYRAL HTN-OFF MED Pilot, 2017 ⁹	Symplcity Spyrall (multi-electrode RF)	RDN vs sham (1:1)	80	Uncontrolled office and 24-hr BP in the absence of antihypertensive drugs	Change in 24-hr SBP at 3 months	-5.5 (95% CI: -9.1 to -2.0) vs -0.5 mmHg (95% CI: -3.9 to 2.90); $p = 0.0414$
RADIANCE-HTN SOLO, 2018 ¹²	Paradise (US)	RDN vs sham (1:1)	146	Uncontrolled daytime ambulatory BP in the absence of antihypertensive drugs	Change in daytime ambulatory SBP at 2 months	-8.5 ± 9.3 vs -2.2 ± 10.0 mmHg; $p = 0.0001$
SPYRAL HTN-ON MED, 2018 ¹⁰	Symplcity Spyrall (multi-electrode RF)	RDN vs sham (1:1)	80	Uncontrolled office and 24-hr BP on 1 to 3 antihypertensive drugs	Change in 24-hr SBP at 6 months	-9.0 (95% CI: -12.7 to -5.3) vs -1.6 mmHg (95% CI: -5.2 to 2.0); $p = 0.006$
SPYRAL HTN-OFF MED Pivotal, 2020 ¹¹	Symplcity Spyrall (multi-electrode RF)	Bayesian adaptive design, RDN vs sham (1:1)	331	Uncontrolled office and 24-hr BP, in the absence of antihypertensive drugs	Change in 24-hr SBP at 3 months	-4.7 (95% CI: -6.4 to -2.9) vs -0.6 mmHg (95% CI: -2.1 to 0.9); $p = 0.0005$
RADIANCE-HTN TRIO, 2021 ¹³	Paradise (US)	RDN vs sham (1:1)	136	Uncontrolled office and daytime ambulatory BP on 3 antihypertensive drugs	Change in daytime ambulatory SBP at 2 months	-8.0 (IQR $-16.4, 0.0$) vs -3.0 mmHg (IQR $-10.3, 1.8$); $p = 0.022$
REQUIRE, 2022 ¹⁹	Paradise (US)	RDN vs sham (1:1)	143	Uncontrolled office and 24-hr BP on ≥ 3 antihypertensive drugs	Change in daytime ambulatory SBP at 3 months	-6.6 (95% CI: -10.4 to -2.8) vs -6.5 mmHg (95% CI: -10.3 to -2.7); $p = 0.971$

BP: blood pressure; CI: confidence interval; IQR: interquartile ratio; RDN: renal denervation; RF: radiofrequency; SBP: systolic blood pressure; SSAHT: standardised stepped-care antihypertensive treatment; US: ultrasound

The highest-quality trials are multicentre, randomised, sham-controlled and blinded (patients and outcome assessors) trials using ambulatory BP as the primary efficacy outcome.

The Symplcity HTN-3 trial did not demonstrate the BP-lowering efficacy of a mono-electrode radiofrequency (RF) catheter system

compared with a sham procedure at 6 months¹⁶. However, several methodological limitations of this trial, including frequent medication changes, limited training and experience of the proceduralists, likely incomplete circumferential ablation in most patients¹⁷, as well as new insights on renal nerve distribution¹⁸, informed the design

Table 2. Ongoing sham-controlled RCTs (as of June 2022).

Trial, NCT*	Catheter system	Design, (randomisation ratio)	Sample size	Inclusion criteria	Primary efficacy outcome	Estimated trial completion
SPYRAL HTN-ON MED Expansion, NCT02439775	Symlicity Spyral (multi-electrode RF)	Bayesian adaptive design, RDN vs sham (1:1)	340	Uncontrolled office and 24-hour BP on 1-3 antihypertensive drugs	Change in 24-hour SBP at 6 months	2026
RADIANCE II, NCT03614260	Paradise (US)	RDN vs sham (1:1)	225	Uncontrolled stage II hypertension (office and daytime ambulatory BP) in absence of antihypertensive drugs	Change in daytime ambulatory SBP at 2 months	2022
TARGET BP OFF-MED, NCT03503773	Peregrine (ethanol injection via microneedles)	RDN vs sham (1:1)	90	Uncontrolled office and 24-hour BP in absence of antihypertensive drugs	Change in 24-hour ambulatory SBP at 2 months	2023
TARGET BP I, NCT02910414	Peregrine (ethanol injection via microneedles)	RDN vs sham (1:1)	300	Uncontrolled office and 24-hour BP on 2-5 antihypertensive drugs	Change in ambulatory 24-hour SBP at 3 months	2025
*NCTs found at ClinicalTrials.gov. BP: blood pressure; RDN: renal denervation; RF: radiofrequency; SBP: systolic blood pressure; US: ultrasound						

of the second-generation RDN trials. These used revised catheter technologies and procedural techniques in patients with uncontrolled hypertension. Four sham-controlled trials⁹⁻¹³, conducted after the publication of the Symlicity HTN-3 trial, fulfilled all of these methodological criteria (**Supplementary Table 1**).

In the second generation of sham-controlled trials, RF and ultrasound RDN reduced ambulatory and office BP in patients without (proof of concept) and with antihypertensive drugs (**Figure 2**)⁹⁻¹³. In three of these RCTs^{9-11,13}, non-adherence to antihypertensive medications – assessed using ultra-high-performance liquid chromatography-tandem mass spectrometry to detect drugs or their metabolites in blood and urine – was dynamic and frequently observed in both the RDN and the sham groups¹⁰. Importantly, RDN lowered BP over the 24-hour circadian cycle, described as an “always-on” effect independent of pharmacokinetics, drug adherence, and dosing schemes (**Figure 3**). To achieve similar persistent BP-lowering efficacy over 24 hours, antihypertensive medications need to be taken daily and have a long pharmacokinetic/pharmacodynamic half-life. The last published trial conducted in Japan and the Republic of Korea, the REQUIRE trial, did not meet its primary efficacy endpoint of a change in 24-hour ambulatory systolic BP at 3 months due to similar BP reductions in the RDN and sham groups¹⁹. When interpreting the trial, several shortcomings in the trial design and conduct have to be considered: i) concomitant antihypertensive medication was not standardised, ii) medication adherence was not objectively assessed, iii) treating physicians were not blinded to treatment allocation, and iv) home and 24-hour ambulatory BP changes were inconsistent¹⁹. Importantly, four ongoing sham-controlled RCTs fulfil the above-mentioned scientific quality criteria (**Table 2, Supplementary Table 1**).

Since the publication of the 2018 ESC/ESH Guidelines for the Management of Arterial Hypertension, several high-quality, randomised, sham-controlled trials⁹⁻¹³ have been published, demonstrating a BP-lowering efficacy over 24 hours for both RF and

ultrasound RDN in a broad spectrum of patients whose hypertension ranges from mild-to-moderate to severe and resistant.

SAFETY

In addition to the RCTs, well-conducted registries provide short- and long-term safety data on RDN²⁰. Possible acute procedure-related events are summarised in **Table 3**. After reviewing the available data (**Supplementary Table 2**), the experts did not identify any specific safety concerns associated with RDN beyond the expected complication rates of a transfemoral arterial access procedure (less than 1%) and the patients’ exposure to radiation²¹. In the Symlicity HTN-3 trial, the largest sham-controlled randomised trial investigating RDN, 1 of 364 patients (0.3%) had a vascular access site complication²². The radiation dose varies depending on several factors, including patient characteristics (i.e., obesity, renal artery anatomy), the interventionalist’s experience, and the number of ablation attempts.

There is no evidence of significant procedure-related safety concerns beyond the risks associated with femoral arterial access.

Possible long-term concerns are both the development of *de novo* renal artery stenosis secondary to vascular injury induced by RDN²³ and worsening kidney function. In a meta-analysis of 50 studies including 5,769 patients (10,249 patient-years) undergoing RF-RDN, the pooled annual incidence rate for renal artery stenting was 0.2%²⁴, similar to the reported natural incidence of renal artery stenosis in arterial hypertension²⁵. Importantly, 79% of all events occurred within one year post-procedure²⁴. RCTs systematically using non-invasive renal artery imaging one year after the procedure have been reassuring regarding the vascular safety of RDN^{9-13,16}. Moreover, no acute kidney injury or time-dependent decrease in kidney function was reported. A meta-analysis of 48 studies including 2,381 patients showed no significant change in the estimated glomerular filtration rate (eGFR) after a mean follow-up of 9.1 months²⁶. In the Global SYMPPLICITY Registry, the observed eGFR decrease over three years was within the expected time-dependent eGFR decline in patients with severe




Figure 2. Mean BP change in second-generation sham-controlled RDN trials. Mean change in office (A) and 24-hour (B) systolic BP in second-generation sham-controlled RDN trials. The SPYRAL HTN-OFF MED Pivotal trial used a Bayesian design with an informative prior (outcome analyses included data from the pilot and pivotal trials). Data are mean and 95% confidence intervals (CI). BP: blood pressure

hypertension²⁰. Only 0.3% of the patients without chronic kidney disease at baseline had new onset end-stage kidney disease at the 3-year follow-up²⁷. During the long-term follow-up of the SPYRAL HTN-ON MED trial, changes in eGFR and serum creatinine from baseline to 36 months did not differ between the RDN and sham groups²⁸. In the 4-year follow-up of patients with resistant hypertension included in the Symplicity HTN-3 trial, the rate of new-onset end-stage kidney disease was 5%²². Of note, patients with an eGFR of <40 ml/min/1.73 m² have been excluded from all sham-controlled trials⁹⁻¹³. Thus, renal safety can only be considered in patients with normal or mildly-to-moderately reduced kidney function (Kidney Disease Improving Global Outcomes [KDIGO] stage G1 to G3a). Another limitation refers to the lack of follow-up extending beyond three years.

Long-term follow-up data up to three years did not reveal any significant increase in de novo renal artery stenosis (<1%) or

worsening kidney function beyond the expected rates in hypertensive patients with normal or mildly-to-moderately reduced kidney function.

DURABILITY

There are questions regarding functional reinnervation of the kidneys following RDN. In hypertensive sheep with chronic kidney disease, partial regrowth of renal nerves and return of function were reported 30 months after RDN²⁹. In contrast, permanent axonal destruction and sustained reductions in renal noradrenaline were documented in a porcine model³⁰. Long-term follow-up data from the Global SYMPPLICITY Registry²⁰, the SPYRAL HTN-ON MED trial²⁸ and the RADIANCE-HTN SOLO trial³¹ indicate that the BP-lowering efficacy of RDN in patients with hypertension is sustained for at least up to three years, with a trend for continuous BP reduction over time (Figure 4). The demonstration




Figure 3. Twenty-four-hour ambulatory BP profile at baseline and 2-month follow-up in the RADIANCE HTN-TRIO trial. Change in systolic BP in the renal denervation (A) and sham groups (B). Hourly BP data are mean±standard errors (SE). Changes between baseline and follow-up are median (interquartile range [IQR]). Adapted with permission from¹³. BP: blood pressure

of durability can be challenging because of dynamic changes in medications, lifestyle interventions, development of coexisting illnesses, ageing, etc¹⁵.

Data from registries and sham-controlled trials indicate a sustained BP-lowering effect of RDN for up to three years.

Patient selection

According to the 2018 ESC/ESH Guidelines for the Management of Arterial Hypertension, hypertension is defined as an office systolic BP ≥ 140 mmHg and/or diastolic BP ≥ 90 mmHg measured with a validated oscillometric electronic device using repeated measurements on repeat occasions, confirmed by out-of-office BP measurements, including home BP or ambulatory BP monitoring⁸. In most patients, BP-lowering treatment is recommended if

their office BP exceeds $\geq 140/\geq 90$ mmHg, taking into account their CV risk, hypertension-mediated organ damage and established CV or renal diseases⁸. It is recommended to target an office BP of $<140/<90$ mmHg in all patients, if tolerated. In patients aged <70 years, office systolic BP should be further lowered to 120–129 mmHg, if tolerated^{8,32}. Lowering systolic BP <130 mmHg in fit older patients might be effective and safe, but BP treatment targets should be individualised for very old and frail patients³³. A diastolic BP target of <80 mmHg should be considered for all patients⁸.

The definition of hypertension and thresholds for treatment initiation (including lifestyle modification and antihypertensive drugs) are based on the 2018 ESC/ESH Guidelines for the Management of Arterial Hypertension⁸.

Table 3. Possible procedural complications and preventive measures.

Complications	Preventive measures/management strategies
Access-site vascular complication, i.e., haematoma, pseudoaneurysm, fistula, bleeding, etc.	US-guided puncture, vascular closure device, blood pressure control
Contrast-induced acute kidney injury	Adequate (preprocedural) hydration, minimal contrast volume (or diluted contrast)
Vascular complications, i.e., renal artery spasm, dissections, distal perforation, intracapsular renal haematoma, renal artery stenosis/dissections, aortic dissection, embolisation	Non-selective abdominal aorta angiogram, no-touch technique to selectively engage the renal artery, avoidance of hydrophilic guidewires, proper RDN technique, intra-arterial injection of a vasodilator, availability of adequately sized stents on site in case of acute renal artery complication which cannot be reversed by prolonged renal artery ballooning
RDN: renal denervation; US: ultrasound	

Treatment of hypertension traditionally starts with lifestyle modifications, including restriction of sodium intake (<2 g sodium per day), reduction of alcohol (<100 g per week), weight loss, smoking cessation, and regular aerobic exercise⁸. However, lifestyle modifications should not defer the initiation of antihypertensive medications, especially in patients with grade 3 hypertension and in patients at high or very high CV risk⁸. In most patients, pharmacotherapy using dual single-pill combination therapy consisting of a renin-angiotensin-system (RAS) blocker (angiotensin-converting enzyme inhibitor or angiotensin receptor blocker) and a calcium channel blocker (CCB) or thiazide/thiazide-like diuretic should be initiated⁸. Triple-drug combination therapy, including an RAS blocker, CCB, and a thiazide/thiazide-like diuretic, ideally as a single pill, is recommended if BP remains above target⁸.

Resistant hypertension is defined as uncontrolled office BP ($\geq 140/\geq 90$ mmHg), which is confirmed by out-of-office BP measurements, despite appropriate lifestyle changes and the intake of a triple-drug combination, including a diuretic at maximally tolerated doses⁸. Diagnosing resistant hypertension requires the exclusion of pseudo-resistant hypertension and secondary hypertension causes, including mainly primary hyperaldosteronism, renovascular disease, and chronic kidney disease. A frequently underestimated cause of pseudo-resistant hypertension is partial adherence (ranging from 13% to 46%) or full non-adherence (ranging from 2% to 35%) to prescribed antihypertensive therapy^{8,34}.

Non-adherence to antihypertensive medication represents a major barrier to BP control and should be screened for in all patients with uncontrolled hypertension.

If resistant hypertension is confirmed, low-dose spironolactone (25-50 mg daily) is recommended in addition to the existing triple-drug therapy⁸. If spironolactone is not tolerated or contraindicated, eplerenone, amiloride, or higher doses of diuretics, beta

blockers or doxazosin are recommended⁸. Of note, eplerenone is not marketed for hypertension in various countries. If eplerenone is used, higher doses (i.e., 50-200 mg daily) may be necessary to achieve a BP-lowering effect³⁵. Many of these fourth-line agents do not have evidence supporting an impact on CV outcomes but have been shown to reduce BP in clinical trials.

RDN IN RESISTANT HYPERTENSION

RDN was shown to reduce BP in adult patients with uncontrolled hypertension in addition to antihypertensive drugs^{10,13}, including resistant hypertension¹³. **Supplementary Table 3** summarises the inclusion criteria of completed sham-controlled trials. The available evidence also suggests that RDN has an acceptable safety profile. This is particularly important as the procedural risk of an interventional therapy must not exceed the risk from the underlying condition itself³⁶. According to the available evidence, this expert group suggests considering RDN in patients with uncontrolled hypertension despite treatment with ≥ 3 antihypertensive drugs in appropriate doses, including a diuretic, confirmed by an out-of-office BP measurement, preferably ambulatory BP measurement, (i.e., resistant hypertension) and an eGFR ≥ 40 ml/min/1.73 m². It is strongly advised to exclude secondary causes of hypertension before RDN is considered.

RDN may be used in adult patients with uncontrolled resistant hypertension (office BP $\geq 140/\geq 90$ mmHg confirmed by 24-hour ambulatory systolic BP ≥ 130 mmHg or daytime systolic BP ≥ 135 mmHg) treated with ≥ 3 antihypertensive drugs and an eGFR ≥ 40 ml/min/1.73 m².

Patients who are non-adherent or intolerant to multiple antihypertensive drugs, particularly first-line agents and spironolactone, may also be candidates for RDN. These patients may, therefore, be on fewer than 3 drugs at the time of their selection for RDN due to their prior drug intolerance.

RDN may be a possible treatment option for patients unable to tolerate antihypertensive drugs in the long term or patients who express a preference to undergo RDN in a tailored, shared decision-making process.

Of note, patients with isolated systolic hypertension were excluded from the recent sham-controlled trials⁹⁻¹³. There is evidence from *post hoc* analyses that patients with isolated systolic hypertension might exhibit a less pronounced BP-lowering effect following RDN^{37,38}. However, data derived from the Global SYMPPLICITY Registry³⁹ and the RADIOSOUND trial⁴⁰ demonstrated comparable efficacy in patients with and without isolated systolic hypertension.

In the absence of evidence, it is not advised to perform RDN in kidney transplant recipients or patients with severely impaired kidney function (KDIGO stage G4 and G5), including patients with fibromuscular dysplasia, untreated secondary hypertension, a single functioning kidney or who require haemodialysis.

HYPERTENSION-MEDIATED ORGAN DAMAGE AND CV RISK

The coexistence of other CV risk factors with hypertension^{41,42} exponentially increases the risk of CV events, such as myocardial




Figure 4. Mean change in 24-hour BP from baseline up to 36 months in the SPYRAL HTN-ON MED trial. A) 24-hour systolic BP. B) 24-hour diastolic BP. *Mean sham-control measurements at 36 months include 13 imputed crossover patients' BP values from the most recent measurements before the RDN procedure. Error bars are standard errors (SE). Adapted with permission from²⁸. BP: blood pressure

infarction, stroke, and death^{43,44}. Hypertensive patients with coronary artery or cerebrovascular disease have the highest absolute CV risk in whom BP-lowering results in greater absolute risk reductions⁴⁵. Although high-risk populations (end-stage kidney disease, post-myocardial infarction, heart failure, uncontrolled type II or type I diabetes) were excluded from recent sham-controlled RDN trials, this expert group advises considering the global CV risk, hypertension-mediated organ damage and established CV complications in decision-making since BP control is of the utmost importance in these patients. As recommended by recent guidelines, CV risk may be assessed using the Systematic Coronary Risk Estimation 2 (SCORE2) and Systematic Coronary Risk Estimation 2-Older Persons (SCORE2-OP) risk algorithms

for fatal and non-fatal (myocardial infarction, stroke) CV disease³². Moreover, RDN may have beneficial effects beyond the antihypertensive effect in patients with comorbidities associated with increased sympathetic nervous system activation.

The patient's global CV risk should be evaluated, accounting for hypertension-mediated organ damage and CV complications. High CV risk favours the use of RDN.

PATIENT PREFERENCE

Some patients are unwilling or unable to take antihypertensive drugs or increase their medication burden, especially if they have associated comorbid conditions. Patients recently diagnosed with hypertension and not receiving therapy had the highest preference

for RDN⁴⁶. In a recent survey, 38% of the medication-naïve participants stated that they would prefer RDN over taking anti-hypertensive drugs⁴⁷. Even though education and empowerment of patients were shown to have a beneficial effect on drug adherence⁴⁸, these approaches were often unsuccessful in further reducing BP⁴⁹. In another survey, patients who regarded hypertension as a major concern strongly preferred RDN⁴⁶. The amount of BP reduction followed by durability has been identified as the most relevant determinant of patient preference for an antihypertensive therapy (drugs or devices) (Weber M, et al. Patient preferences for interventional and pharmaceutical treatments among US adults with uncontrolled hypertension. TCT 2021. Orlando, FL, USA). Understanding the patients' situations and exploring their goals and preferences is central to the shared decision-making process. Moreover, the shared decision-making process requires that the patient is well informed about the benefits and limitations of RDN and the possible risks associated with the procedure. The patient should be aware that in all RCTs, a large between-patient variability in BP response to RDN of multiple origins was observed (including lack of post-procedural feedback of effective renal nerve ablation and variability in the procedure, in medications added after RDN, in drug adherence, and in the individual pathophysiology of hypertension). None of the predictors of BP response to RDN reported so far are sensitive and specific enough to allow an individualised patient selection. In light of the available evidence from sham-controlled trials⁹⁻¹², RDN may be applied in patients with uncontrolled hypertension on fewer than 3 drugs, if they express a strong preference for RDN after intensive counselling on RDN and alternative treatment options, including lifestyle modification and medications.

The decision-making process should incorporate the preference of a well-informed and educated patient. To optimise the shared decision-making, patients must be fully informed about the benefits/limitations and risks associated with RDN.

Centre selection

A multidisciplinary hypertension team (MDHT) should oversee RDN programmes and should include experts on hypertension and percutaneous CV interventions. The MDHT may also involve a clinical cardiologist, angiologist and/or nephrologist in some healthcare systems. The hypertension expert should have a clinical focus on hypertension management and verified expertise in assessing secondary hypertension, ideally recognised as a hypertension specialist by accredited bodies such as the ESH. The interventionalists need specific training in RDN procedures. The MDHT meets regularly and documents the indications of RDN and related management strategies.

Multidisciplinary hypertension teams involving experts on hypertension and percutaneous CV interventions should evaluate the indication and perform RDN.

To qualify for an RDN programme, the centre should have a hypertension outpatient clinic, inpatient ward, radiology division, clinical and hormonal laboratory, catheterisation laboratory,

coronary care or intensive care unit, and access to an emergent vascular surgery facility, either onsite or remote.

Training

To set up an RDN centre, extensive training is required, which should include:

1. access-site management (i.e., proficiency in femoral artery puncture and haemostasis), radioprotection measures (considering the young age of some patients undergoing RDN), knowledge of digital subtraction angiography, contrast-sparing techniques, renal artery anatomy and nerve distribution (**Figure 5**), selective renal artery catheterisation, and periprocedural BP management and analgesia/sedation;
2. hands-on training using a bench model (demo or simulator) of at least one clinically validated and commercially available device;
3. offsite attendance of an active RDN centre to acquire insights on the organisational structure, including the procedure, patient preparation and follow-up;
4. performance of at least five proctored RDN cases with each device intended to be used at the site.

The procedure should be performed by a highly skilled interventionalist with experience in renal artery interventions to avoid high complication rates, as observed in renal artery revascularisation trials^{50,51}, and to minimise the risk of ineffective treatments related to suboptimal interventions. In some countries, national societies have provided recommendations on the minimum number of renal artery interventions (RDN or angioplasty/stenting) to be performed per site and/or operator⁴⁸.

Preprocedural imaging

Preprocedural planning should include non-invasive renal artery imaging to anticipate anatomical peculiarities (e.g., presence of accessory arteries) and screen for anatomical ineligibility criteria (e.g., inappropriate vessel diameter), such as untreated severe atherosclerotic renal artery disease or fibromuscular dysplasia. The choice of imaging modality should be based on patient characteristics (e.g., obesity), expected image quality, availability, and local expertise³⁶. Even though duplex ultrasound is preferred as a screening method due to its widespread availability, low costs, and the avoidance of radiation and contrast dye, it is highly observer-dependent and may not provide images of sufficient quality, especially in obese patients. Computed tomography angiography (CTA) or magnetic resonance angiography (MRA) are the preferred imaging procedures that can detect adrenal and renal artery abnormalities, especially in the work-up of patients with resistant hypertension. However, selective renal angiography immediately before RDN remains the gold standard since CTA or MRA may miss some renal artery abnormalities which preclude RDN, such as fibromuscular dysplasia.

Procedural considerations

The required patient preparation is reported in **Table 4**. **Supplementary Table 4** lists the necessary toolbox for RDN




Figure 5. Schematic illustration of the renal artery with its surrounding nerves. The sympathetic nerve fibres originate from the abdominal ganglia and run conically to the distal part of the vessel. The lower circles show the nerve distribution stratified according to the total number (each green dot represents 10 nerves) and relative number (as percent per segment) of nerves. Adapted with permission from⁹¹.

Table 4. Patient preparation.

Adequate hydration as per contrast media-based procedure
Intraprocedural administration UFH (1000 U/kg to target ACT >250 sec)
Periprocedural administration of an aspirin loading dose, followed by aspirin 75-100 mg for 1 month post-procedure
Patients on OAC are managed according to the CCS guidelines related to endovascular interventions ⁹⁹
Analgesia and sedation according to the Monitored Anaesthesia Care approach: low doses of opioids (e.g., morphine 1-3 mg or fentanyl 1-2 mcg/kg intravenously [i.v.]) and benzodiazepine (e.g., midazolam 2-3 mg i.v.)
Intraprocedural monitoring of vital parameters
Drugs for management of adverse events must be available in the catheter laboratory (e.g., naloxone and flumazenil)
Intravenous drugs for blood pressure control (e.g., nitroprusside, urapidil, nitroglycerine, phentolamine)
ACT: activated clotting time; CCS: chronic coronary syndrome; OAC: oral anticoagulants; UFH: unfractionated heparin.

procedures. The efficacy and safety of the multi-electrode Symplicity Spyral RDN catheter system (Medtronic) and the Paradise ultrasound catheter system (ReCor) have been documented in sham-controlled trials. The specific features of the devices are outlined in **Table 5**.

With current-generation RDN devices, femoral arterial access is needed, ideally using sonographic guidance. Successful haemostasis with closure devices is advisable to shorten hospital stays, especially in patients with uncontrolled hypertension who are overweight or obese.

Table 5. Specific considerations related to the RDN device.

	Symplicity Spyral RF catheter system	Paradise US catheter system
Anatomical eligibility criteria	Treatment of all accessible arteries with a diameter of 3-8 mm	Treatment of accessible main renal arteries with a diameter of 3-8 mm
Access	Femoral access (6 Fr)	Femoral access (7 Fr)
Wiring	Consider use of extra-support wires or buddy wires in tortuous anatomy	Consider use of extra-support wires or buddy wires in tortuous anatomy
Ablation sites	Main renal artery and branches	Main renal artery, 2-3 ablations per artery. The selection of catheter size and ablation site required preprocedural planning with CT/MRA in trials. Final sizing can be done during the renal angiogram before the procedure
Arterial wall contact	Ensure appropriate contact of the RF electrodes and the vessel wall Ensure energy delivery (for at least 45 sec, ideally 60 sec)	Ensure complete occlusion of the renal artery after balloon inflation
Duration	Simultaneous ablation at 4 points (for at least 45 sec, ideally 60 sec)	7 seconds per ablation
CT: computed tomography; MRA: magnetic resonance angiography; RF: radiofrequency; US: ultrasound		

Most RDN procedures can be performed using a single posterior-anterior projection of the kidney. In tortuous anatomies, the ideal placement for energy delivery may be obscured by overlapping vascular branches and, hence, difficult to identify. In these cases, cranial or caudal projections in ipsilateral oblique positions are helpful. Modern angiography systems allow good-quality fluoroscopic image acquisition without cine filming to reduce the radiation dose. A global aortography centred on the kidneys can help identify artery origins and accessory renal arteries. At the end of the RDN procedure, angiography of the renal arteries should be performed to assess potential renal parenchymal or arterial injuries.

Standard operating procedures are suggested for each device to achieve the most effective renal nerve ablation in optimal periprocedural patient security conditions.

Several potential approaches (e.g., transvascular pacing⁵², arterial flow and resistance⁵³, renal artery vasodilation)⁵⁴ have been investigated in preclinical and clinical studies to intraprocedurally confirm successful RDN. There is no validated, easily applicable periprocedural clinical indicator of successful renal nerve ablation. Whether this is partly related to the fact that complete interruption of sympathetic nerves surrounding the renal arteries occurs after up to 90 days post-procedure remains to be shown⁵⁵. Periprocedural complications and possible preventive measures and management strategies are summarised in **Table 3**.

At present, there is no validated, easily applicable periprocedural clinical indicator of successful renal nerve ablation.

Clinical trial design considerations

SELECTION OF CONTROLS: SHAM OR NO SHAM?

The US Food and Drug Administration requires sham-controlled trials for device-based therapies for hypertension, where feasible and ethical⁵⁶. A recent meta-analysis suggests that the standardised mean difference for primary efficacy outcomes between invasive interventions and sham procedures was small to moderate, which underlines the influence of non-specific effects on trial outcomes and an overestimation of the clinical efficacy of interventions in many circumstances¹⁴. Although the risk of adverse events following the sham procedure was low for most trials included in the meta-analysis¹⁴, exposing patients to risk by referring them to an invasive sham procedure can raise ethical concerns. The number of patients allocated to a sham procedure should be minimised as much as possible. While some studies suggest that the invasiveness of a sham procedure correlates with its effectiveness⁵⁷, the necessary invasiveness of a sham procedure in hypertension trials remains unclear. A trial investigating whether each step of the current sham procedure (i.e., skin puncture, femoral/radial access, and angiogram) is needed for the patient's blinding would be desirable. Importantly, adequate blinding of participants and outcome assessors should be established and assessed⁵⁸. Further, implementing blinding indices to ensure the absence of bias is advised.

Pooled standardised data from control patients of randomised, sham-controlled trials could be used as an historical control group to avoid exposing patients to invasive placebo procedures and reduce costs⁵⁹.

For devices approved in certain indications, allocating patients to a sham procedure can be avoided. Comparisons with an active comparator, for example, an already approved device (or drug therapy), could be an alternative.

It is anticipated that future trials comparing two active device treatments could be designed as active-controlled, non-inferiority trials, rather than sham-controlled trials. However, such trials would require larger sample sizes and tight non-inferiority margins for safety and efficacy to be clinically relevant⁶⁰.

FOLLOW-UP DURATION

A follow-up duration of 8 to 12 weeks was sufficient to demonstrate the BP-lowering efficacy of RDN in the absence of antihypertensive medications^{9,11,12}. However, in contrast to antihypertensive medications, where no further BP decrease is seen after 8 to 12 weeks^{61,62}, sustained and meaningful BP reductions were documented up to 36 months after RDN independently from concomitant antihypertensive medication burden^{28,31}. Even though renal sympathetic reinnervation is a theoretical concern, regrown nerves do not regain normal function^{29,63}. Investigation of longer-term efficacy may be challenging because of i) the unblinding of patients and outcome assessors (performance bias), ii) crossover to RDN of patients initially allocated to the control group, iii)

age- and body weight-dependent longitudinal BP changes, iv) the addition of antihypertensive medications to facilitate BP control, v) dynamic changes in drug adherence over time, vi) possible lifestyle modifications, and vii) development of a coexisting illness. A placebo-controlled, randomised withdrawal of antihypertensive medications for a limited period of 4 to 6 weeks could be used to assess long-term efficacy after 12 and 24 months^{36,64}. However, assessing BP during a washout period may equally be limited by confounding factors independent of medication adherence.

Well-designed registries with standardised protocols to collect comparable data from one device to another at similar timepoints and follow-up duration and that are regularly monitored for data accuracy and completeness should be conducted to detect adverse events in a real-world setting for up to three years. Registries should allow annual safety, post-market surveillance and performance reports.

STATISTICAL CONSIDERATIONS

Adaptive designs modifying the course of a trial following pre-specified rules have been introduced in addition to the traditional fixed trial design¹¹. Using an adaptive trial design might be more efficient, resource-saving, and ethically favourable as unnecessary enrolment of patients can be avoided⁶⁵. While conventional reporting of composite outcomes and time-to-event analyses do not reflect the clinical importance of an event⁶⁶, hierarchical approaches, such as the Finkelstein-Schoenfeld method⁶⁷ and the win ratio⁶⁶, prioritise more clinically relevant events and allow the combination of BP outcomes with patient-centred or patient-reported outcomes¹⁵.

META-ANALYSES

This expert group suggests performing an individual patient-level meta-analysis of all second-generation RCTs once the four currently ongoing sham-controlled trials of high scientific quality have been completed. Such a meta-analysis could provide additional information on the preferred target patient groups and facilitate the performance of a robust cost-effectiveness analysis, which might be crucial for implementing RDN in hypertension management across different national healthcare systems. Limitations should be acknowledged, including differing RDN methods, variability in endpoint assessment, and absence/presence of medications, among other factors. An independent academic investigator group should perform such a meta-analysis.

The currently available meta-analyses on RDN aggregate data from studies of different designs and data quality, which may impact the efficacy and safety assessments. The highest-quality meta-analysis requires individual patient-level data from the second-generation RDN trials.

BP OUTCOMES

As BP is a continuous and dynamic variable, office, home, and 24-hour ambulatory BP measurements are complementary approaches to accurately define BP response to treatment⁶⁸. Office

BP measurements are widely available, inexpensive and, if performed according to guidelines⁸, accurate. Office BP has been used in most landmark hypertension trials and is most commonly used for hypertension management in clinical practice⁸. Averaging BP determined during several visits might further increase the precision of office BP.

Out-of-office BP, including home and 24-hour ambulatory BP, eliminates the white-coat effect. Home BP predicts CV morbidity and mortality better than office BP⁶⁹ and might improve medication adherence. Twenty-four-hour ambulatory BP is less prone to bias and regression to the mean. Moreover, 24-hour BP, especially night-time BP, has a stronger association with hypertension-mediated organ damage and CV outcomes than office BP⁷⁰⁻⁷². More sophisticated BP measures, including visit-to-visit variability⁷³ and time in the BP target range⁷⁴, might be useful as additional outcomes of RDN trials. Cuffless wearable devices are currently being validated⁷⁵ and may be utilised in future trials to assess real-time BP, heart rate, activity and sleeping patterns.

ASSESSMENT OF MEDICATION BURDEN AND DRUG ADHERENCE

Knowledge of medication changes and drug adherence is crucial when assessing BP changes following RDN. Non-adherence to antihypertensive medication is common (including approximately 50% of patients with “treatment-resistant hypertension”)³⁴ and associated with poor clinical outcomes⁷⁶. Assessing drug adherence is complicated by non-uniform usage of definitions and a lack of gold-standard methodology⁷⁷, reflecting the dynamic changes in adherence over time^{10,49}.

While most studies investigating antihypertensive treatment used simplified dichotomous measures to report medication burden (e.g., number of pills, number of medications, number of daily doses), several more detailed indices have been introduced recently to quantify the medication burden (**Supplementary Table 5**)²⁸. All of these indices have limitations, and none can perfectly reflect the complex pharmacokinetics and dynamic characteristics of interactions between antihypertensive medications²⁸. The use of registry data for dispensed medications over long-term follow-up may provide additional information about adherence and persistence to the prescribed therapy⁷⁸. Urine and plasma are the most commonly used matrices for assessing drug adherence. Drug adherence monitoring in urine is impacted by the long washout periods of several antihypertensive drugs, which often last longer than multiple half-lives, usually exceeding 24 hours.

ASSESSMENT OF CV MORBIDITY AND MORTALITY

First-line agents recommended by the guidelines have been shown to reduce fatal and non-fatal events. Other antihypertensive treatments (e.g., exercise, metabolic surgery, mineralocorticoid receptor antagonists, clonidine, moxonidine, doxazosin, minoxidil, and hydralazine) are recommended by current guidelines, because these approaches have been shown to lower BP⁸. Still, their impact on CV outcomes has not been prospectively investigated⁸.

BP-lowering is an accepted surrogate marker of the reduction of CV morbidity and mortality^{8,79}. In a meta-analysis of individual patient-level data, including data for 344,716 participants from 48 randomised trials of pharmacological BP-lowering medications, a 5 mmHg reduction of systolic BP reduced the risk of major adverse CV events (MACE) by about 10%, irrespective of previous diagnoses of CV disease⁸⁰. The proportional risk reductions for stroke, ischaemic heart disease, heart failure, and CV death were 13%, 8%, 13%, and 5%, respectively⁸⁰. There is no suggestion that the clinical benefit achieved through BP-lowering should differ whether achieved by medications, device-based therapies, or their combination. Outcome trials for RDN are challenging to conduct as confounding is likely (changes in adherence, lifestyle modification, etc.), they are expensive, long-term follow-up (>3 years) is required, and the residual risk, as observed in the SPRINT⁸¹ and STEP³³ trials, is very low nowadays, especially in high-income countries. Of note, we calculated that in order to detect the impact of an intervention that reduces office systolic BP by 10 mmHg, conferring a 20% reduction in MACE³ in an RCT in a population with an annual MACE rate of 3.5%³³, would require a randomised sample size of 19,544 patients to achieve a power of 80%, with an overall 2-sided alpha level of 0.05.

HYPERTENSION-MEDIATED ORGAN DAMAGE

In the absence of outcome data, conducting well-designed studies and registries investigating the impact of RDN on hypertension-mediated organ damage as an intermediate endpoint, such as left ventricular hypertrophy or urinary albumin excretion, becomes more important. A meta-analysis, including several observational studies, suggested that RDN may improve hypertension-mediated organ damage (regression of left ventricular mass, improved diastolic function)⁸². However, high-risk patient populations (those with end-stage kidney disease, post-myocardial infarction, heart failure, diabetes mellitus) who might benefit the most from BP-lowering were excluded from most studies.

PATIENT-RELATED OUTCOMES

In line with the Hypertension Academic Research Consortium (HARC)¹⁵, we advocate validating patient-related outcome measures (PROMs) in hypertension and systematically including them in RDN trials using health-related quality of life questionnaires (e.g., the European Quality of Life 5-Dimension 3 Level [EQ-5D-3L] and the short-form health survey [SF36]).

INDICATIONS OTHER THAN HYPERTENSION

RDN is under investigation as a complementary approach for indications associated with increased sympathetic nervous system activity beyond hypertension (**Figure 6**). In patients with paroxysmal atrial fibrillation and uncontrolled hypertension, RDN combined with pulmonary vein isolation (PVI) reduced atrial fibrillation (AF) recurrence compared with PVI alone^{83,84}. In several animal models of heart failure, RDN improved autonomic balance, decreased renin-angiotensin system activity, and reduced




Figure 6. Potential future indications for RDN beyond hypertension (currently under investigation). HF: heart failure; RDN: renal denervation

cardiac remodelling⁸⁵⁻⁸⁷. Large prospective trials assessing the safety and efficacy of RDN in disease states other than hypertension are advocated.

IMPACT OF COVID-19 ON RDN TRIALS

The COVID-19 pandemic has impacted health, lifestyle, and socioeconomic aspects of daily living, which might cause increased variability and variation in BP⁸⁸ and affect clinical trial conduct by various means (**Supplementary Figure 1**)⁸⁸⁻⁹⁰. Surveys incorporating the patient's self-reported health status and depression may provide additional perspective on observed BP patterns.

OPEN QUESTIONS

Although sham-controlled trials have confirmed the BP-lowering efficacy and safety of RDN in patients without and with anti-hypertensive drugs, including patients with treatment-resistant hypertension, several questions remain unanswered. First, other than high baseline BP, none of the investigated patient characteristics, haemodynamic parameters or biomarkers have been identified as a consistent predictor for treatment response. Second, there is no simple and reliable method to confirm successful RDN intraprocedurally. Third, the usefulness of repeat RDN among individuals with persistent uncontrolled hypertension has not been investigated. Fourth, while radial arterial access has been established for percutaneous coronary intervention and subsequently demonstrated to lead to a lower risk of access-site complications, no dedicated catheter system is yet commercially available for transradial RDN. Fifth, the value of sympathetic denervation of organs besides the kidney is unclear and remains to be investigated. Sixth, well-designed cost-effectiveness studies for RDN are lacking.

Conclusions

Since the publication of the 2018 ESC/ESH Guidelines for the Management of Arterial Hypertension, several sham-controlled trials of high methodological quality have been published, demonstrating the safety and the BP-lowering efficacy of RF and ultrasound RDN. Therefore, RDN now represents another treatment option in adult patients with uncontrolled resistant hypertension confirmed by ambulatory BP measurements. RDN may also be used in selected patients deemed intolerant to antihypertensive drugs long term following an expert review. The shared decision-making process should incorporate the preference of a well-informed patient and individual CV risk. MDHTs involving experienced experts on hypertension and percutaneous CV interventions should evaluate the indication and perform RDN. Proceduralists require expertise in renal interventions and specific training in RDN procedures, and centres performing RDN should be able to treat any potential complications. Ongoing studies and future research might answer open questions and are needed to investigate RDN for indications other than hypertension.

Appendix. Authors' affiliations

1. Department of Clinical and Molecular Medicine, Sapienza University of Rome, Rome, Italy; 2. Paris Centre de Recherche Cardiovasculaire, INSERM, Université Paris Cité, Paris, France; 3. Hypertension Department, AP-HP, Hôpital Européen Georges-Pompidou, Paris, France and FCRIN INI-CRCT, Université de Lorraine, Nancy, France; 4. Department of Nephrology and Hypertension, University Hospital Erlangen, Erlangen, Germany and Friedrich Alexander University Erlangen-Nürnberg, Erlangen, Germany; 5. Klinik für Innere Medizin III, Universitätsklinikum des Saarlandes and Saarland University, Homburg, Germany; 6. Cardiovascular Center Aalst, OLV Hospital Aalst, Aalst, Belgium and Department of Experimental Pharmacology, Faculty of Medicine and Pharmacy, Vrije Universiteit Brussel, Brussels, Belgium; 7. Pharmacology Unit, AP-HP, Hôpital Européen Georges-Pompidou, Paris, France; 8. Institute of Cardiology, Jagiellonian University Medical College, Krakow, Poland and GVM Care & Research, Maria Cecilia Hospital, Cotignola, Italy; 9. Department of Clinical Sciences, Karolinska Institute, Solna, Sweden and Division of Cardiovascular Medicine, Danderyd Hospital, Stockholm, Sweden and Department of Cardiology, Danderyd University Hospital Corporation, Stockholm, Sweden; 10. Piedmont Heart Institute, Atlanta, GA, USA; 11. Department of Cardiology, Royal Brompton and Harefield Hospitals, London, UK, and National Heart and Lung Institute, Imperial College, London, UK, and School of Cardiovascular Medicine and Sciences, Kings College London, London, UK, and Center for Molecular Cardiology, University of Zurich, Schlieren, Switzerland; 12. Department of Medicine and Surgery, University of Milano-Bicocca, Milan, Italy and Cardiology Unit, Istituto Auxologico Italiano, IRCCS, Milan, Italy; 13. Department of Cardiovascular Medicine, Centre Hospitalier Princesse Grace, Monte Carlo, Monaco; 14. Division of Cardiology, Department of Medicine, University of Verona, Verona,

Italy; 15. Dobney Hypertension Centre, Medical School, Perth, WA, Australia, and Royal Perth Hospital Unit, Medical Research Foundation, The University of Western Australia, Perth, WA, Australia and Departments of Cardiology and Nephrology, Royal Perth Hospital, Perth, WA, Australia; 16. Department of Cardiology, University Hospital of Wales, Cardiff, UK; 17. Department of Cardiology, University Heart Center, University Hospital Zurich, Zurich, Switzerland; 18. Department of Cardiology, Sapienza University of Rome, Sant'Andrea Hospital, Rome, Italy; 19. 1st Department of Cardiology, National and Kapodistrian University of Athens, Athens, Greece and Hippocratio Hospital, Athens, Greece; 20. The Lambe Institute for Translational Medicine, Galway, Ireland and University of Galway, Galway, Ireland; 21. The Smart Sensors Lab, London, UK and CURAM, London, UK

Acknowledgements

The Coordination Committee consists of Michel Azizi, Emanuele Barbato, Lucas Lauder, Felix Mahfoud, Roland E. Schmieder, Costas Tsioufis, and William Wijns. We are grateful to Armin Schweitzer for his help with the artwork. We would also like to thank Claire Jackson-Blanchet from the Europa Group for her assistance with organisation and logistics.

Conflict of interest statement

E. Barbato has received speaker honoraria from BSCI, Abbott, OpSens, and Insight Lifetech. M. Azizi has received grant support and non-financial support from ReCor Medical and Idorsia; and has received consulting fees from Medtronic, AstraZeneca, Alnylam Pharmaceutical, Poxel Pharma, and Novartis. R.E. Schmieder has received scientific support and grants from Medtronic, ReCor Medical, and Ablative Solutions to the institution; has received honoraria for lectures from Ablative Solutions, Apontis, AstraZeneca, Bayer, Boehringer Ingelheim, Lilly, MENARINI, Medtronic, Novo Nordisk, Novartis, ReCor Medical, and Servier; and honoraria for advisory board activities from Ablative Solutions, Apontis, AstraZeneca, Bayer, Boehringer Ingelheim, Lilly, MENARINI, Medtronic, Novo Nordisk, Novartis, ReCor Medical, and Servier. L. Lauder reports speaker honoraria from Medtronic and ReCor Medical. M. Böhm reports personal fees from Abbott, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Vifor, Servier, Medtronic, and Novartis; and grants from Deutsche Forschungsgemeinschaft and AstraZeneca. S. Brouwers has received speaker honoraria from Sanofi, Daiichi Sankyo, Servier, MENARINI, and Merck through the institution. R.M. Bruno is supported by H2020 InSiDe (grant agreement No 871547) and has received speaker honoraria from Medtronic. T. Kahan reports research grants to the Karolinska Institute from Medtronic and ReCor Medical, all outside the submitted work. D.E. Kandzari has received institutional research and grant support from Medtronic and Ablative solutions; personal consulting honoraria from Medtronic and Ablative Solutions; and has equity in BioStar Ventures, but none related to Ablative Solutions. T.F. Lüscher has received research and educational grants to the institution from

Abbott, Amgen, AstraZeneca, Boehringer Ingelheim, Daiichi-Sankyo, Novartis, Sanofi, Servier and Vifor, outside this work; and honoraria from Abbott India, Acthera, Cor2ED, Dacadoo, Daiichi-Sankyo, Novo Nordisk and Pfizer, unrelated to this work. G. Parati reports speaker honoraria from Omron Healthcare, Bayer, and Servier. A. Pathak reports consultancy/speaker honoraria from Medtronic, ReCor Medical, and Ablative Solutions. F.L. Ribichini has received scientific support and speaker honoraria from Medtronic. M.P. Schlaich is supported by an NHMRC Research Fellowship and has received consulting fees, and/or travel and research support from Medtronic, Abbott, ReCor Medical, Novartis, Servier, Pfizer, and Boehringer Ingelheim. A.S.P. Sharp reports consultancy/speaker honoraria from Medtronic, ReCor Medical, Philips, and Boston Scientific. I. Sudano has received consulting fees from Amgen, AstraZeneca, Daiichi Sankyo, MSD, Medtronic, Novartis, Novo Nordisk, Recordati, Sanofi, and Servier; travel grants from Amgen, AstraZeneca, Daiichi Sankyo, MSD, Medtronic, Novartis, Novo Nordisk, Recordati, Sanofi, and Servier; and honoraria from Amgen, AstraZeneca, Daiichi Sankyo, MSD, Medtronic, Novartis, Novo Nordisk, Recordati, Sanofi, and Servier. M. Volpe has received honoraria from the speakers bureaus at AstraZeneca, Novartis, Boehringer Ingelheim, Bayer, and Amgen; has received payments for scientific collaborations from MENARINI, Servier, Novo Nordisk, Novartis, and Sanofi; has a contract of collaboration with Medtronic but did not receive fees; is a member of the Kalos Medical advisory board. C. Tsioufis has received grants or honoraria from Medtronic, ReCor Medical, AstraZeneca, Bayer, Boehringer Ingelheim, MENARINI, Elpen, Win Medica, Vianex, Novartis, and Servier. W. Wijns reports institutional grants and honoraria from MicroPort; and is the co-founder of Argonauts, an innovation facilitator. F. Mahfoud is supported by Deutsche Gesellschaft für Kardiologie (DGK), Deutsche Forschungsgemeinschaft (SFB TRR219), and Deutsche Herzstiftung. He has received scientific support (to the institution) from Ablative Solutions, Medtronic, and ReCor Medical; and speaker honoraria from Ablative Solutions, AstraZeneca, Bayer, Boehringer Ingelheim, Inari, Medtronic, Merck, and ReCor Medical. The other authors have no conflicts of interest to declare.

References

1. GBD 2019 Risk Factors Collaborators. Global burden of 87 risk factors in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. *Lancet*. 2020;396:1223-49.
2. NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants. *Lancet*. 2021;398:957-80.
3. Ettehad D, Emdin CA, Kiran A, Anderson SG, Callender T, Emberson J, Chalmers J, Rodgers A, Rahimi K. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. *Lancet*. 2016;387:957-67.
4. Bundy JD, Li C, Stuchlik P, Bu X, Kelly TN, Mills KT, He H, Chen J, Whelton PK, He J. Systolic Blood Pressure Reduction and Risk of Cardiovascular Disease and Mortality: A Systematic Review and Network Meta-analysis. *JAMA Cardiol*. 2017;2:775-81.
5. Aggarwal R, Chiu N, Wadhera RK, Moran AE, Raber I, Shen C, Yeh RW, Kazi DS. Racial/Ethnic Disparities in Hypertension Prevalence, Awareness, Treatment, and Control in the United States, 2013 to 2018. *Hypertension*. 2021;78:1719-26.

6. Egan BM, Li J, Sutherland SE, Rakotz MK, Wozniak GD. Hypertension Control in the United States 2009 to 2018: Factors Underlying Falling Control Rates During 2015 to 2018 Across Age- and Race-Ethnicity Groups. *Hypertension*. 2021;78:578-87.
7. Lauder L, Azizi M, Kirtane AJ, Böhm M, Mahfoud F. Device-based therapies for arterial hypertension. *Nat Rev Cardiol*. 2020;17:614-28.
8. Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, Clement DL, Coca A, de Simone G, Dominiczak A, Kahan T, Mahfoud F, Redon J, Ruilope L, Zanchetti A, Kerins M, Kjeldsen SE, Kreutz R, Laurent S, Lip GYH, McManus R, Narkiewicz K, Ruschitzka F, Schmieder RE, Shlyakhto E, Tsioufis C, Aboyans V, Desormais I; ESC Scientific Document Group. 2018 ESC/ESH Guidelines for the management of arterial hypertension. *Eur Heart J*. 2018;39:2021-104.
9. Townsend RR, Mahfoud F, Kandzari DE, Kario K, Pocock S, Weber MA, Ewen S, Tsioufis K, Tousoulis D, Sharp ASP, Watkinson AF, Schmieder RE, Schmid A, Choi JW, East C, Walton A, Hopper I, Cohen DL, Wilensky R, Lee DP, Ma A, Devireddy CM, Lea JP, Lurz PC, Flegler K, Davies J, Chapman N, Cohen SA, DeBruin V, Fahy M, Jones DE, Rothman M, Böhm M; SPYRAL HTN-OFF MED trial investigators*. Catheter-based renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications (SPYRAL HTN-OFF MED): a randomised, sham-controlled, proof-of-concept trial. *Lancet*. 2017;390:2160-70.
10. Kandzari DE, Böhm M, Mahfoud F, Townsend RR, Weber MA, Pocock S, Tsioufis K, Tousoulis D, Choi JW, East C, Brar S, Cohen SA, Fahy M, Pilcher G, Kario K; SPYRAL HTN-ON MED Trial Investigators. Effect of renal denervation on blood pressure in the presence of antihypertensive drugs: 6-month efficacy and safety results from the SPYRAL HTN-ON MED proof-of-concept randomised trial. *Lancet*. 2018;391:2346-55.
11. Böhm M, Kario K, Kandzari DE, Mahfoud F, Weber MA, Schmieder RE, Tsioufis K, Pocock S, Konstantinidis D, Choi JW, East C, Lee DP, Ma A, Ewen S, Cohen DL, Wilensky R, Devireddy CM, Lea J, Schmid A, Weil J, Agdirlioglu T, Reedus D, Jefferson BK, Reyes D, D'Souza R, Sharp ASP, Sharif F, Fahy M, DeBruin V, Cohen SA, Brar S, Townsend RR; SPYRAL HTN-OFF MED Pivotal Investigators. Efficacy of catheter-based renal denervation in the absence of antihypertensive medications (SPYRAL HTN-OFF MED Pivotal): a multicentre, randomised, sham-controlled trial. *Lancet*. 2020;395:1444-51.
12. Azizi M, Schmieder RE, Mahfoud F, Weber MA, Daemen J, Davies J, Basile J, Kirtane AJ, Wang Y, Lobo MD, Saxena M, Feyz L, Rader F, Lurz P, Sayer J, Sapoval M, Levy T, Sanghvi K, Abraham J, Sharp ASP, Fisher NDL, Bloch MJ, Reeve-Stoffer H, Coleman L, Mullin C, Mauri L; RADIANCE-HTN Investigators. Endovascular ultrasound renal denervation to treat hypertension (RADIANCE-HTN SOLO): a multicentre, international, single-blind, randomised, sham-controlled trial. *Lancet*. 2018;391:2335-45.
13. Azizi M, Sanghvi K, Saxena M, Gosse P, Reilly JP, Levy T, Rump LC, Persu A, Basile J, Bloch MJ, Daemen J, Lobo MD, Mahfoud F, Schmieder RE, Sharp ASP, Weber MA, Sapoval M, Fong P, Pathak A, Lantelme P, Hsi D, Bangalore S, Witkowski A, Weil J, Kably B, Barman NC, Reeve-Stoffer H, Coleman L, McClure CK, Kirtane AJ; RADIANCE-HTN investigators. Ultrasound renal denervation for hypertension resistant to a triple medication pill (RADIANCE-HTN TRIO): a randomised, multicentre, single-blind, sham-controlled trial. *Lancet*. 2021;397:2476-86.
14. Lauder L, da Costa BR, Ewen S, Scholz SS, Wijns W, Lüscher TF, Serruys PW, Edelman ER, Capodanno D, Böhm M, Jüni P, Mahfoud F. Randomized trials of invasive cardiovascular interventions that include a placebo control: a systematic review and meta-analysis. *Eur Heart J*. 2020;41:2556-69.
15. Kandzari DE, Mahfoud F, Weber MA, Townsend R, Parati G, Fisher NDL, Lobo MD, Bloch M, Böhm M, Sharp ASP, Schmieder RE, Azizi M, Schlaich MP, Papademetriou V, Kirtane AJ, Daemen J, Pathak A, Ukena C, Lurz P, Grassi G, Myers M, Finn AV, Morice MC, Mehran R, Jüni P, Stone GW, Krucoff MW, Whelton PK, Tsioufis K, Cutlip DE, Spitzer E. Clinical Trial Design Principles and Outcomes Definitions for Device-Based Therapies for Hypertension: A Consensus Document From the Hypertension Academic Research Consortium. *Circulation*. 2022;145:847-63.
16. Bhatt DL, Kandzari DE, O'Neill WW, D'Agostino R, Flack JM, Katzen BT, Leon MB, Liu M, Mauri L, Negoita M, Cohen SA, Oparil S, Rocha-Singh K, Townsend RR, Bakris GL; SYMPLICITY HTN-3 Investigators. A controlled trial of renal denervation for resistant hypertension. *N Engl J Med*. 2014;370:1393-401.
17. Kandzari DE, Bhatt DL, Brar S, Devireddy CM, Esler M, Fahy M, Flack JM, Katzen BT, Lea J, Lee DP, Leon MB, Ma A, Massaro J, Mauri L, Oparil S, O'Neill WW, Patel MR, Rocha-Singh K, Sobotka PA, Svetkey L, Townsend RR, Bakris GL. Predictors of blood pressure response in the SYMPLICITY HTN-3 trial. *Eur Heart J*. 2015;36:219-27.
18. Sakakura K, Ladich E, Cheng Q, Otsuka F, Yahagi K, Fowler DR, Kolodgie FD, Virmani R, Joner M. Anatomic assessment of sympathetic peri-arterial renal nerves in man. *J Am Coll Cardiol*. 2014;64:635-43.
19. Kario K, Yokoi Y, Okamura K, Fujihara M, Ogozawa Y, Yamamoto E, Urata H, Cho JM, Kim CJ, Choi SH, Shinohara K, Mukai Y, Ikemoto T, Nakamura M, Seki S, Matoba S, Shibata Y, Sugawara S, Yumoto K, Tamura K, Yoshihara F, Nakamura S, Kang WC, Shibasaki T, Dote K, Yokoi H, Matsuo A, Fujita H, Takahashi T, Kang HJ, Sakata Y, Horie K, Inoue N, Sasaki KI, Ueno T, Tomita H, Morino Y, Nojima Y, Kim CJ, Matsumoto T, Kai H, Nanto S. Catheter-based ultrasound renal denervation in patients with resistant hypertension: the randomized, controlled REQUIRE trial. *Hypertens Res*. 2022;45:221-31.
20. Mahfoud F, Böhm M, Schmieder R, Narkiewicz K, Ewen S, Ruilope L, Schlaich M, Williams B, Fahy M, Mancia G. Effects of renal denervation on kidney function and long-term outcomes: 3-year follow-up from the Global SYMPLICITY Registry. *Eur Heart J*. 2019;40:3474-82.
21. Applegate RJ, Sacrinty MT, Kutcher MA, Kahl FR, Gandhi SK, Santos RM, Little WC.. Trends in vascular complications after diagnostic cardiac catheterization and percutaneous coronary intervention via the femoral artery, 1998 to 2007. *JACC Cardiovasc Interv*. 2008;1:317-26.
22. Bhatt DL, Vaduganathan M, Kandzari DE, Leon MB, Rocha-Singh K, Townsend RR, Katzen BT, Oparil S, Brar S, DeBruin V, Fahy M, Bakris GL; SYMPLICITY HTN-3 Steering Committee Investigators. Long-term outcomes after catheter-based renal artery denervation for resistant hypertension: final follow-up of the randomised SYMPLICITY HTN-3 Trial. *Lancet*. 2022;400:1405-16.
23. Templin C, Jaguszewski M, Ghadri JR, Sudano I, Gaehwiler R, Hellermann JP, Schoenenberger-Berzins R, Landmesser U, Erne P, Noll G, Lüscher TF. Vascular lesions induced by renal nerve ablation as assessed by optical coherence tomography: pre- and post-procedural comparison with the Simplicity catheter system and the EnligHTN multi-electrode renal denervation catheter. *Eur Heart J*. 2013;34:2141-8.
24. Townsend RR, Walton A, Hettrick DA, Hickey GL, Weil J, Sharp ASP, Blankstijn PJ, Böhm M, Mancia G. Review and meta-analysis of renal artery damage following percutaneous renal denervation with radiofrequency renal artery ablation. *EuroIntervention*. 2020;16:89-96.
25. Chrysochou C, Kalra PA. Epidemiology and natural history of atherosclerotic renovascular disease. *Prog Cardiovasc Dis*. 2009;52:184-95.
26. Sanders MF, Reitsma JB, Morpey M, Gremmels H, Bots ML, Pisano A, Bolignano D, Zoccali C, Blankstijn PJ. Renal safety of catheter-based renal denervation: systematic review and meta-analysis. *Nephrol Dial Transplant*. 2017;32:1440-7.
27. Ott C, Mahfoud F, Mancia G, Narkiewicz K, Ruilope LM, Fahy M, Schlaich MP, Böhm M, Schmieder RE. Renal denervation in patients with versus without chronic kidney disease: results from the Global SYMPLICITY Registry with follow-up data of 3 years. *Nephrol Dial Transplant*. 2022;37:304-10.
28. Mahfoud F, Kandzari DE, Kario K, Townsend RR, Weber MA, Schmieder RE, Tsioufis K, Pocock S, Dimitriadis K, Choi JW, East C, D'Souza R, Sharp ASP, Ewen S, Walton A, Hopper I, Brar S, McKenna P, Fahy M, Böhm M. Long-term efficacy and safety of renal denervation in the presence of antihypertensive drugs (SPYRAL HTN-ON MED): a randomised, sham-controlled trial. *Lancet*. 2022;399:1401-10.
29. Singh RR, McArdle ZM, Iudica M, Easton LK, Booth LC, May CN, Parkington HC, Lombardo P, Head GA, Lambert G, Moritz KM, Schlaich MP, Denton KM. Sustained Decrease in Blood Pressure and Reduced Anatomical and Functional Reinnervation of Renal Nerves in Hypertensive Sheep 30 Months After Catheter-Based Renal Denervation. *Hypertension*. 2019;73:718-27.
30. Sharp ASP, Tunev S, Schlaich M, Lee DP, Finn AV, Trudel J, Hettrick DA, Mahfoud F, Kandzari DE. Histological evidence supporting the durability of successful radiofrequency renal denervation in a normotensive porcine model. *J Hypertens*. 2022;40:2068-75.
31. Rader F, Kirtane AJ, Wang Y, Daemen J, Lurz P, Sayer J, Saxena M, Levy T, Scicli AP, Thackeray L, Azizi M, Weber MA. Durability of blood pressure reduction after ultrasound renal denervation: three-year follow-up of the treatment arm of the randomised RADIANCE-HTN SOLO trial. *EuroIntervention*. 2022;18:e677-85.
32. Visseren FLJ, Mach F, Smulders YM, Carballo D, Koskinas KC, Bäck M, Benetos A, Biffi A, Boavida JM, Capodanno D, Cosyns B, Crawford C, Davos CH, Desormais I, Di Angelantonio E, Franco OH, Halvorsen S, Hobbs FDR, Hollander M, Jankowska EA, Michal M, Sacco S, Sattar N, Tokgozoglul L, Tonstad S, Tsioufis KP, van Dis I, van Gelder IC, Wannan C, Williams B; ESC National Cardiac Societies; ESC Scientific Document Group. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. *Eur Heart J*. 2021;42:3227-337.
33. Zhang W, Zhang S, Deng Y, Wu S, Ren J, Sun G, Yang J, Jiang Y, Xu X, Wang TD, Chen Y, Li Y, Yao L, Li D, Wang L, Shen X, Yin X, Liu W, Zhou X, Zhu B, Guo Z, Liu H, Chen X, Feng Y, Tian G, Gao X, Kario K, Cai J; STEP Study Group. Trial of Intensive Blood-Pressure Control in Older Patients with Hypertension. *N Engl J Med*. 2021;385:1268-79.
34. Berra E, Azizi M, Capron A, Hoieggan A, Rabbia F, Kjeldsen SE, Staessen JA, Wallemacq P, Persu A. Evaluation of Adherence Should Become an Integral Part of Assessment of Patients With Apparently Treatment-Resistant Hypertension. *Hypertension*. 2016;68:297-306.
35. Tam TS, Wu MH, Masson SC, Tsang MP, Stabler SN, Kinkade A, Tung A, Tejani AM. Eplerenone for hypertension. *Cochrane Database Syst Rev*. 2017;2:CD008996.

36. Mahfoud F, Azizi M, Ewen S, Pathak A, Ukena C, Blankestijn PJ, Bohm M, Burnier M, Chatellier G, Durand Zaleski I, Grassi G, Joner M, Kandzari DE, Kirtane A, Kjeldsen SE, Lobo MD, Lüscher TF, McEvoy JW, Parati G, Rossignol P, Ruilope L, Schlaich MP, Shahzad A, Sharif F, Sharp ASP, Sievert H, Volpe M, Weber MA, Schmieder RE, Tsioufis C, Wijns W. Proceedings from the 3rd European Clinical Consensus Conference for clinical trials in device-based hypertension therapies. *Eur Heart J*. 2020;41:1588-99.
37. Ewen S, Ukena C, Linz D, Kindermann I, Cremers B, Laufs U, Wagenpfeil S, Schmieder RE, Böhm M, Mahfoud F. Reduced effect of percutaneous renal denervation on blood pressure in patients with isolated systolic hypertension. *Hypertension*. 2015;65:193-9.
38. Mahfoud F, Bakris G, Bhatt DL, Esler M, Ewen S, Fahy M, Kandzari D, Kario K, Mancia G, Weber M, Böhm M. Reduced blood pressure-lowering effect of catheter-based renal denervation in patients with isolated systolic hypertension: data from SYMPLICITY HTN-3 and the Global SYMPLICITY Registry. *Eur Heart J*. 2017;38:93-100.
39. Mahfoud F, Mancia G, Schmieder R, Narkiewicz K, Ruilope L, Schlaich M, Whitbourn R, Zirikli A, Zeller T, Stawowy P, Cohen SA, Fahy M, Böhm M. Renal Denervation in High-Risk Patients With Hypertension. *J Am Coll Cardiol*. 2020;75:2879-88.
40. Fengler K, Rommel KP, Lapusca R, Blazek S, Besler C, Hartung P, von Roeder M, Kresoja KP, Desch S, Thiele H, Lurz P. Renal Denervation in Isolated Systolic Hypertension Using Different Catheter Techniques and Technologies. *Hypertension*. 2019;74:341-8.
41. Power C, Atherton K, Manor O. Co-occurrence of risk factors for cardiovascular disease by social class: 1958 British birth cohort. *J Epidemiol Community Health*. 2008;62:1030-5.
42. Roth GA, Mensah GA, Johnson CO, Addolorato G, Ammirati E, Baddour LM, Barengo NC, Beaton AZ, Benjamin EJ, Benziger CP, Bonny A, Brauer M, Brodmann M, Cahill TJ, Carapetis J, Catapano AL, Chugh SS, Cooper LT, Coresh J, Criqui M, DeCleene N, Eagle KA, Emmons-Bell S, Feigin VL, Fernández-Solà J, Fowkes G, Gakidou E, Grundy SM, He FJ, Howard G, Hu F, Inker L, Karthikeyan G, Kassebaum N, Koroshetz W, Lavie C, Lloyd-Jones D, Lu HS, Mirijello A, Temesgen AM, Mokdad A, Moran AE, Muntner P, Narula J, Neal B, Ntseke M, Moraes de Oliveira G, Otto C, Owolabi M, Pratt M, Rajagopalan S, Reitsma M, Ribeiro ALP, Rigotti N, Rodgers A, Sable C, Shakil S, Sliwa-Hahnle K, Stark B, Sundström J, Timpel P, Tleyjeh IM, Valgimigli M, Vos T, Whelton PK, Yacoub M, Zuhke L, Murray C, Fuster V; GBD-NHLBI-JACC Global Burden of Cardiovascular Diseases Writing Group. Global Burden of Cardiovascular Diseases and Risk Factors, 1990-2019: Update From the GBD 2019 Study. *J Am Coll Cardiol*. 2020;76:2982-3021.
43. Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, McQueen M, Budaj A, Pais P, Varigos J, Lisheng L; INTERHEART Study Investigators. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. *Lancet*. 2004;364:937-52.
44. Berry JD, Dyer A, Cai X, Garside DB, Ning H, Thomas A, Greenland P, Van Horn L, Tracy RP, Lloyd-Jones DM. Lifetime risks of cardiovascular disease. *N Engl J Med*. 2012;366:321-9.
45. Blood Pressure Lowering Treatment Trialists' Collaboration. Blood pressure-lowering treatment based on cardiovascular risk: a meta-analysis of individual patient data. *Lancet*. 2014;384:591-8.
46. Schmieder RE, Kandzari DE, Wang TD, Lee YH, Lazarus G, Pathak A. Differences in patient and physician perspectives on pharmaceutical therapy and renal denervation for the management of hypertension. *J Hypertens*. 2021;39:162-8.
47. Schmieder RE, Högerl K, Jung S, Bramlage P, Veelken R, Ott C. Patient preference for therapies in hypertension: a cross-sectional survey of German patients. *Clin Res Cardiol*. 2019;108:1331-42.
48. Mahfoud Felix, Galle Jan, Schunkert Heribert, Schmieder Roland E, Rump Lars C, Limbourg Florian P, van der Giet Markus, Elsässer Albrecht, Kintscher Ulrich, Böhm Michael, Weil Joachim. Criteria of the German Cardiac Society (DGK), the German Hypertension League DHL®/German Society for Hypertension and Prevention and the German Society for Nephrology (DGN) on certification of renal denervation centers (RDZ)—Update (published in German) 2021 Jul. Available from: *Kardiologie* 15, 463–470. <https://doi.org/10.1007/s12181-021-00492-7>. Last accessed: 16 December 2022.
49. Burnier M, Egan BM. Adherence in Hypertension. *Circ Res*. 2019;124:1124-40.
50. Astral Investigators, Wheatley K, Ives N, Gray R, Kalra PA, Moss JG, Baigent C, Carr S, Chalmers N, Eadington D, Hamilton G, Lipkin G, Nicholson A, Scoble J. Revascularization versus medical therapy for renal-artery stenosis. *N Engl J Med*. 2009;361:1953-62.
51. Bax L, Woittiez AJ, Kouwenberg HJ, Mali WP, Buskens E, Beek FJ, Braam B, Huysmans FT, Schultze Kool LJ, Rutten MJ, Doorenbos CJ, Aarts JC, Rabelink TJ, Plouin PF, Raynaud A, van Montfrans GA, Reekers JA, van den Meiracker AH, Pattnayam PM, van de Ven PJ, Vroegindewij D, Kroon AA, de Haan MW, Postma CT, Beutler JJ. Stent placement in patients with atherosclerotic renal artery stenosis and impaired renal function: a randomized trial. *Ann Intern Med*. 2009;150:840-8.
52. Qian PC, Barry MA, Lu J, Pouliopoulos J, Mina A, Bandodkar S, Alvarez S, James V, Ronquillo J, Varikatt W, Thiagalangam A, Thomas SP. Transvascular Pacing of Aorticorenal Ganglia Provides a Testable Procedural Endpoint for Renal Artery Denervation. *JACC Cardiovasc Interv*. 2019;12:1109-20.
53. Tsioufis C, Papademetriou V, Dimitriadis K, Tsiachris D, Thomopoulos C, Park E, Hata C, Papalois A, Stefanadis C. Catheter-based renal sympathetic denervation exerts acute and chronic effects on renal hemodynamics in swine. *Int J Cardiol*. 2013;168:987-92.
54. Chen W, Du H, Lu J, Ling Z, Long Y, Xu Y, Xiao P, Gyawali L, Woo K, Yin Y, Zrenner B. Renal Artery Vasodilation May Be An Indicator of Successful Sympathetic Nerve Damage During Renal Denervation Procedure. *Sci Rep*. 2016;6:37218.
55. Rousele SD, Dillon KN, Rousselle-Sabiak TH, Brady DA, Tunev S, Tellez A. Historical Incidence of Spontaneous Lesions in Kidneys from Naive Swine Utilized In Interventional Renal Denervation Studies. *J Cardiovasc Transl Res*. 2016;9:360-7.
56. Khalid N, Rogers T, Shlofmitz E, Chen Y, Dan K, Torguson R, Weintraub WS, Waksman R. Overview of the 2018 US Food and Drug Administration Circulatory System Devices Panel Meeting on Device-Based Therapies for hypertension. *Cardiovasc Revasc Med*. 2019;20:891-6.
57. Meissner K, Fässler M, Rücker G, Kleijnen J, Hróbjartsson A, Schneider A, Antes G, Linde K. Differential effectiveness of placebo treatments: a systematic review of migraine prophylaxis. *JAMA Intern Med*. 2013;173:1941-51.
58. Boutron I, Estellat C, Guittet L, Dechartres A, Sackett DL, Hróbjartsson A, Ravaud P. Methods of blinding in reports of randomized controlled trials assessing pharmacologic treatments: a systematic review. *PLoS Med*. 2006;3:e425.
59. Pocock SJ. The combination of randomized and historical controls in clinical trials. *J Chronic Dis*. 1976;29:175-88.
60. Kaji AH, Lewis RJ. Noninferiority Trials: Is a New Treatment Almost as Effective as Another? *JAMA*. 2015;313:2371-2.
61. Schmieder RE, Philipp T, Guerediaga J, Gorostidi M, Smith B, Weissbach N, Maboudian M, Botha J, van Ingen H. Long-term antihypertensive efficacy and safety of the oral direct renin inhibitor aliskiren: a 12-month randomized, double-blind comparator trial with hydrochlorothiazide. *Circulation*. 2009;119:417-25.
62. Neutel JM, Cushman WC, Lloyd E, Barger B, Handley A. Comparison of long-term safety of fixed-dose combinations azilsartan medoxomil/chlorthalidone vs olmesartan medoxomil/hydrochlorothiazide. *J Clin Hypertens (Greenwich)*. 2017;19:874-83.
63. Booth LC, Nishi EE, Yao ST, Ramchandra R, Lambert GW, Schlaich MP, May CN. Reinnervation of renal afferent and efferent nerves at 5.5 and 11 months after catheter-based radiofrequency renal denervation in sheep. *Hypertension*. 2015;65:393-400.
64. Center for Drug Evaluation and Research. Principles for clinical evaluation of new antihypertensive drugs. Available from: <https://www.fda.gov/regulatory-information/search-fda-guidance-documents/e12a-principles-clinical-evaluation-new-antihypertensive-drugs>. Last accessed: 12 December 2022.
65. Pallmann P, Bedding AW, Choodari-Oskooei B, Dimairo M, Flight L, Hampson LV, Holmes J, Mander AP, Odondi L, Sydes MR, Villar SS, Wason JMS, Weir CJ, Wheeler GM, Yap C, Jaki T. Adaptive designs in clinical trials: why use them, and how to run and report them. *BMC Med*. 2018;16:29.
66. Pocock SJ, Ariti CA, Collier TJ, Wang D. The win ratio: a new approach to the analysis of composite endpoints in clinical trials based on clinical priorities. *Eur Heart J*. 2012;33:176-82.
67. Finkelstein DM, Schoenfeld DA. Combining mortality and longitudinal measures in clinical trials. *Stat Med*. 1999;18:1341-54.
68. Schutte AE, Kollias A, Stergiou GS. Blood pressure and its variability: classic and novel measurement techniques. *Nat Rev Cardiol*. 2022;19:643-54.
69. Ward AM, Takahashi O, Stevens R, Heneghan C. Home measurement of blood pressure and cardiovascular disease: systematic review and meta-analysis of prospective studies. *J Hypertens*. 2012;30:449-56.
70. Mancia G, Facchetti R, Seravalle G, Cuspidi C, Corrao G, Grassi G. Adding Home and/or Ambulatory Blood Pressure to Office Blood Pressure for Cardiovascular Risk Prediction. *Hypertension*. 2021;77:640-9.
71. Yang WY, Melgarejo JD, Thijs L, Zhang ZY, Boggia J, Wei FF, Hansen TW, Asayama K, Ohkubo T, Jeppesen J, Dolan E, Stolarz-Skrzypek K, Malyutina S, Casiglia E, Lind L, Filipovsky J, Maestre GE, Li Y, Wang JG, Imai Y, Kawecka-Jaszcz K, Sandoya E, Narkiewicz K, O'Brien E, Verhamme P, Staessen JA; International Database on Ambulatory Blood Pressure in Relation to Cardiovascular Outcomes (IDACO) Investigators. Association of Office and Ambulatory Blood Pressure With Mortality and Cardiovascular Outcomes. *JAMA*. 2019;322:409-20.
72. Kario K, Hoshida S, Mizuno H, Kabutoya T, Nishizawa M, Yoshida T, Abe H, Katsuya T, Fujita Y, Okazaki O, Yano Y, Tomitani N, Kanegae H; JAMP Study Group. Nighttime Blood Pressure Phenotype and Cardiovascular Prognosis: Practitioner-Based Nationwide JAMP Study. *Circulation*. 2020;142:1810-20.

73. Muntner P, Shimbo D, Tonelli M, Reynolds K, Arnett DK, Oparil S. The relationship between visit-to-visit variability in systolic blood pressure and all-cause mortality in the general population: findings from NHANES III, 1988 to 1994. *Hypertension*. 2011;57:160-6.
74. Fatani N, Dixon DL, Van Tassel BW, Fanikos J, Buckley LF. Systolic Blood Pressure Time in Target Range and Cardiovascular Outcomes in Patients With Hypertension. *J Am Coll Cardiol*. 2021;77:1290-9.
75. Kuwabara M, Harada K, Hishiki Y, Kario K. Validation of two watch-type wearable blood pressure monitors according to the ANSI/AAMI/ISO81060-2:2013 guidelines: Omron HEM-6410T-ZM and HEM-6410T-ZL. *J Clin Hypertens (Greenwich)*. 2019;21:853-8.
76. Kolandaivelu K, Leiden BB, O'Gara PT, Bhatt DL. Non-adherence to cardiovascular medications. *Eur Heart J*. 2014;35:3267-76.
77. Lane D, Lawson A, Burns A, Azizi M, Burnier M, Jones DJL, Kably B, Khunti K, Kreutz R, Patel P, Persu A, Spiering W, Toennes SW, Tomaszewski M, Williams B, Gupta P, Dasgupta I; Endorsed by the European Society of Hypertension (ESH) Working Group on Cardiovascular Pharmacotherapy and Adherence. Nonadherence in Hypertension: How to Develop and Implement Chemical Adherence Testing. *Hypertension*. 2022;79:12-23.
78. Qvarnstrom M, Kahan T, Kieler H, Brandt L, Hasselstrom J, Wettermark B. Medication persistence to antihypertensive drug treatment - a cross-sectional study of attitudes towards hypertension and medication in persistent and non-persistent patients. *Blood Press*. 2019;28:309-16.
79. Blood Pressure Lowering Treatment Trialists' Collaboration. Age-stratified and blood-pressure-stratified effects of blood-pressure-lowering pharmacotherapy for the prevention of cardiovascular disease and death: an individual participant-level data meta-analysis. *Lancet*. 2021;398:1053-64.
80. Blood Pressure Lowering Treatment Trialists' Collaboration. Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis. *Lancet*. 2021;397:1625-1636.
81. SPRINT Research Group, Wright JT Jr, Williamson JD, Whelton PK, Snyder JK, Sink KM, Rocco MV, Reboussin DM, Rahman M, Oparil S, Lewis CE, Kimmel PL, Johnson KC, Goff DC Jr, Fine LJ, Cutler JA, Cushman WC, Cheung AK, Ambrosius WT. A Randomized Trial of Intensive versus Standard Blood-Pressure Control. *N Engl J Med*. 2015;373:2103-16.
82. Kordalis A, Tsiachris D, Pietri P, Tsioufis C, Stefanadis C. Regression of organ damage following renal denervation in resistant hypertension: a meta-analysis. *J Hypertens*. 2018;36:1614-21.
83. Pokushalov E, Romanov A, Corbucci G, Artyomenko S, Baranova V, Turov A, Shirokova N, Karaskov A, Mittal S, Steinberg JS. A randomized comparison of pulmonary vein isolation with versus without concomitant renal artery denervation in patients with refractory symptomatic atrial fibrillation and resistant hypertension. *J Am Coll Cardiol*. 2012;60:1163-70.
84. Steinberg JS, Shabanov V, Ponomarev D, Losik D, Ivanickiy E, Kropotkin E, Polyakov K, Ptaszynski P, Keweloh B, Yao CJ, Pokushalov EA, Romanov AB. Effect of Renal Denervation and Catheter Ablation vs Catheter Ablation Alone on Atrial Fibrillation Recurrence Among Patients With Paroxysmal Atrial Fibrillation and Hypertension: The ERADICATE-AF Randomized Clinical Trial. *JAMA*. 2020;323:248-55.
85. Sharp TE 3rd, Polhemus DJ, Li Z, Spaetra P, Jenkins JS, Reilly JP, White CJ, Kapusta DR, Lefler DJ, Goodchild TT. Renal Denervation Prevents Heart Failure Progression Via Inhibition of the Renin-Angiotensin System. *J Am Coll Cardiol*. 2018;72:2609-21.
86. Polhemus DJ, Trivedi RK, Gao J, Li Z, Scarborough AL, Goodchild TT, Varner KJ, Xia H, Smart FW, Kapusta DR, Lefler DJ. Renal Sympathetic Denervation Protects the Failing Heart Via Inhibition of Neprilysin Activity in the Kidney. *J Am Coll Cardiol*. 2017;70:2139-53.
87. Wang HJ, Wang W, Cornish KG, Rozanski GJ, Zucker IH. Cardiac sympathetic afferent denervation attenuates cardiac remodeling and improves cardiovascular dysfunction in rats with heart failure. *Hypertension*. 2014;64:745-55.
88. Kreutz R, Dobrowolski P, Prejbisz A, Algharably EAE, Bilo G, Creutzig F, Grassi G, Kotsis V, Lovic D, Lurbe E, Modesti PA, Pappacogli M, Parati G, Persu A, Polonia J, Rajzer M, de Timary P, Weber T, Weisser B, Tsioufis K, Mancia G, Januszewicz A; European Society of Hypertension COVID-19 Task Force Review. Lifestyle, psychological, socioeconomic and environmental factors and their impact on hypertension during the coronavirus disease 2019 pandemic. *J Hypertens*. 2021;39:1077-89.
89. Anker SD, Butler J, Khan MS, Abraham WT, Bauersachs J, Bocchi E, Bozkurt B, Braunwald E, Chopra VK, Cleland JG, Ezekowitz J, Filippatos G, Friede T, Hernandez AF, Lam CSP, Lindenfeld J, McMurray JJV, Mehra M, Metra M, Packer M, Pieske B, Pocock SJ, Ponikowski P, Rosano GMC, Teerlink JR, Tsutsui H, Van Veldhuisen DJ, Verma S, Voors AA, Wittes J, Zannad F, Zhang J, Seferovic P, Coats AJS. Conducting clinical trials in heart failure during (and after) the COVID-19 pandemic: an Expert Consensus Position Paper from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). *Eur Heart J*. 2020;41:2109-17.
90. Lansky A, Shah T, Wijns W, Stefanini GG, Farb A, Kaplan A, Xu B, Pietras C, Velazquez E, Serruys PW, Mahfoud F, Baumbach A. Immediate and long-term impact of the COVID-19 pandemic on cardiovascular clinical trials: considerations for study conduct and endpoint determination. *EuroIntervention*. 2020;16:787-93.
91. Lauder L, Wolf MA, Scholz SS, Hohl M, Mahfoud F, Böhm M. Renal Denervation: Is It Ready for Prime Time? *Curr Cardiol Rep*. 2019;21:80.
92. Esler MD, Krum H, Schlaich M, Schmieder RE, Böhm M, Sobotka PA Symplicity HTN-2 Investigators. Renal sympathetic denervation for treatment of drug-resistant hypertension: one-year results from the Symplicity HTN-2 randomized, controlled trial. *Circulation*. 2012;126:2976-82.
93. Azizi M, Sapoval M, Gosse P, Monge M, Bobrie G, Delsart P, Midulla M, Mounier-Véhic C, Courand P-Y, Lantelme P, Denolle T, Dourmap-Collas C, Trillaud H, Pereira H, Plouin PF, Chatellier G; Renal Denervation for Hypertension (DENERHTN) investigators. Optimum and stepped care standardised antihypertensive treatment with or without renal denervation for resistant hypertension (DENERHTN): a multicentre, open-label, randomised controlled trial. *Lancet*. 2015;385:1957-65.
94. Fengler K, Rommel KP, Blazek S, Besler C, Hartung P, von Roeder M, Petzold M, Winkler S, Hollriegel R, Desch S, Thiele H, Lurz P. A Three-Arm Randomized Trial of Different Renal Denervation Devices and Techniques in Patients With Resistant Hypertension (RADIO SOUND-HTN). *Circulation*. 2019;139:590-600.
95. Desch S, Okon T, Heinemann D, Kulle K, Röhnert K, Sonnabend M, Petzold M, Müller U, Schuler G, Eitel I, Thiele H, Lurz P. Randomized sham-controlled trial of renal sympathetic denervation in mild resistant hypertension. *Hypertension*. 2015;65:1202-8.
96. Mathiassen ON, Vase H, Bech JN, Christensen KL, Buus NH, Schroeder AP, Lederballe O, Rickers H, Kampmann U, Poulsen PL, Hansen KW, Btker HE, Peters CD, Engholm M, Bertelsen JB, Lassen JF, Langfeldt S, Andersen G, Pedersen EB, Kaltoft A. Renal denervation in treatment-resistant essential hypertension. A randomized, SHAM-controlled, double-blinded 24-h blood pressure-based trial. *J Hypertens*. 2016;34:1639-47.
97. Schmieder RE, Ott C, Toennes SW, Bramlage P, Gertner M, Dawood O, Baumgart P, O'Brien B, Dasgupta I, Nickenig G, Ormiston J, Saxena M, Sharp ASP, Sievert H, Spinar J, Starek Z, Weil J, Wenzel U, Witkowski A, Lobo MD. Phase II randomized sham-controlled study of renal denervation for individuals with uncontrolled hypertension - WAVE IV. *J Hypertens*. 2018;36:680-9.
98. Weber MA, Kirtane AJ, Weir MR, Radhakrishnan J, Das T, Berk M, Mendelsohn F, Bouchard A, Larrain G, Haase M, Diaz-Cartelle J, Leon MB. The REDUCE HTN: REINFORCE: Randomized, Sham-Controlled Trial of Bipolar Radiofrequency Renal Denervation for the Treatment of Hypertension. *JACC Cardiovasc Interv*. 2020;13:461-70.
99. Knuuti J, Wijns W, Saraste A, Capodanno D, Barbato E, Funck-Brentano C, Prescott E, Storey RF, Deaton C, Cuisset T, Agewall S, Dickstein K, Edvardsen T, Escaned J, Gersh BJ, Svitol P, Gilard M, Hasdai D, Hatala R, Mahfoud F, Masip J, Muneretto C, Valgimigli M, Achenbach S, Bax JJ; ESC Scientific Document Group. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. *Eur Heart J*. 2020;41:407-77.

Supplementary data

Supplementary Table 1. Quality criteria and list of RCT studies.

Supplementary Table 2. Major adverse events in the second generation of sham-controlled trials and large registries.

Supplementary Table 3. Inclusion criteria of completed sham-controlled RDN trials.

Supplementary Table 4. Toolbox for RDN procedures.

Supplementary Table 5. Medication indices to quantify medication burden.

Supplementary Figure 1. Impact of the COVID-19 pandemic on hypertension and the conduct of clinical trials.

The supplementary data are published online at:
<https://eurointervention.pronline.com/doi/10.4244/EIJ-D-22-00723>



Trial name, year of publication	Multi-centre	RCT	Sham control group	Blinding of patients and outcome assessors	ABPM for primary outcome assessment	Study completed as planned	Second generation devices
Target BP OFF, ongoing; NCT03503773	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Target BP I, ongoing; NCT02910414	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Abbreviations: ABPM, ambulatory blood pressure monitoring; RCT, randomised controlled trial.							

Supplementary Table 2. Major adverse events in the second generation of sham-controlled trials and large registries.

Trial	Events in the RDN group
Spyral HTN-OFF MED Pivotal, 2020	1 hospital admission for hypertensive crisis/emergency
Spyral HTN-ON MED, 2018	0 events within 6 months; 2 events during 36-month follow-up: 1 patient in the RDN group had hypertensive crisis and stroke, 1 all-cause death in the sham group.
Radiance-HTN SOLO, 2018	1 pre-existing ostial renal artery stenosis; during 36-month follow-up: 1 TIA, 1 hypertensive event
Radiance-HTN TRIO, 2021	Procedural safety events: 1 femoral access site pseudoaneurysm requiring intervention Other safety events through 2 months: 1 sudden death, 1 acute myocardial infarction, 1 case of doubling of plasma creatinine associated with spironolactone
Global Symplicity Registry, 2019	At 1 year: 3 cases (0.1%*) of newly developed renal artery stenosis At 3 years: 4.0%* of patients experienced death (2.0%* cardiovascular death), 3.2%* stroke, 2.6%* underwent hospitalization for hypertensive crisis, 1.6%* developed end-stage kidney disease, and 1.5%* had an increase in serum creatinine from baseline of >50%
*Data are Kaplan-Meier estimate %. Abbreviations: RDN, renal denervation; TIA, transient ischemic attack.	

Supplementary Table 3. Inclusion criteria of completed sham-controlled RDN trials.


	Spyral HTN-OFF MED (Pilot & Pivotal)	Spyral HTN-ON MED	Radiance-HTN SOLO	Radiance-HTN TRIO
Age, years	20-80	20-80	18-75	18-75
Number of drugs*	0	1-3	0	3 (single-pill combination)
Office BP*, mmHg	Systolic 150-179 and diastolic \geq 90	Systolic 150-179 and diastolic \geq 90		
Ambulatory BP*, mmHg	24-hour systolic: 140-169	24-hour systolic: 140-169	Daytime systolic 135-169 mmHg and diastolic 85-104	Daytime systolic \geq 135 mmHg and diastolic \geq 85
eGFR, ml/min/1.73 m ²	\geq 45	\geq 45	\geq 40	\geq 40
*At randomisation visit. Abbreviations: BP, blood pressure; eGFR, estimated glomerular filtration rate.				

Supplementary Table 4. Toolbox for RDN procedures.

Toolbox for RDN procedures
<ul style="list-style-type: none"> • Ultrasound system with a linear doppler probe • 6-F or 7-F arterial sheath • Seldinger needle • 0.035-inch wire (non-hydrophilic) • 5-F or 6-F pigtail • 6-F short guiding catheter (JR4, IMA, etc.) • 0.014-inch extra-support guidewire (non-hydrophilic) • RDN catheter system (and generator) • Balloons and stents (and covered stents) for treatment of renal arteries • Gelatine sponge, beads, or endovascular coils for the management of vascular complications • Microcatheters • (Vascular closure devices)
Abbreviations: RDN, renal denervation.

Supplementary Table 5. Medication indices to quantify medication burden.

Formula
$Index = \sum_{aHTN\ meds} \left(\frac{prescribed\ dose}{maximum\ recommended\ dose} \right)$
$Index = no.\ of\ aHTN\ meds \sum_{aHTN\ meds} \left(\frac{prescribed\ dose}{maximum\ recommended\ dose} \right)$
$Index = no.\ of\ aHTN\ meds \sum_{aHTN\ meds} \left(class\ weight * \frac{prescribed\ dose}{maximum\ recommended\ dose} \right)$
$Index = \sum_{aHTN\ meds} \left(\frac{prescribed\ dose}{daily\ defined\ dose} \right)$
<p>The daily defined dose is the average maintenance dose per day of a drug used for its main indication in adults. Abbreviations: aHTN meds, antihypertensive medications.</p>



Supplementary Figure 1. Impact of the COVID-19 pandemic on hypertension and the conduct of clinical trials.